Daraxonrasib Pancreatic Cancer: USMLE RAS Inhibitor Review

A new analysis of the phase 3 RASolute 302 trial found that daraxonrasib, an oral targeted drug, improved survival compared with standard chemotherapy in previously treated metastatic pancreatic cancer. The benefit was consistent across several groups, including different RAS mutation types and tumors with no identified RAS mutation. The results were presented at the European Society for Medical Oncology (ESMO) Congress by Dr. Zev Wainberg of the UCLA Health Jonsson Comprehensive Cancer Center.

What happened

RASolute 302 enrolled approximately 500 patients with metastatic pancreatic cancer who had already received treatment. Patients were randomly assigned to daraxonrasib, taken as a daily pill, or to one of several standard chemotherapy regimens.

Earlier results from the trial showed a median survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy. The new analysis asked whether that benefit held up across subgroups. Researchers looked at three variables:

• the type of RAS mutation in the tumor
• the chemotherapy regimen used for comparison
• the setting in which patients had received earlier treatment

Survival outcomes consistently favored daraxonrasib across the RAS mutation groups examined, including patients whose tumors had no identified RAS mutation. The advantage was also consistent across the different chemotherapy comparison groups. This suggests the result was not driven by a comparison with just one regimen.

The researchers collected detailed molecular data on all RAS mutation subsets. Wainberg described the update as the largest analysis of any RAS inhibitor across all RAS mutation subgroups. He also noted that, depending on the individual mutation, daraxonrasib "may have a different response." According to the source, the drug received FDA approval in August 2026 under the brand name RASONQUE. The approval covers adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

Why it matters

Metastatic pancreatic cancer is among the hardest cancers to treat, especially after the disease has progressed on first-line therapy. Against that background, a median survival of 13.2 months versus 6.7 months in a randomized phase 3 trial is a notable signal.

The biology also matters. More than 90% of pancreatic cancers carry mutations in RAS genes. For decades, RAS was considered "undruggable," and the field leaned on cytotoxic chemotherapy. Daraxonrasib is designed to block multiple forms of the active RAS protein, both mutated and nonmutated. A drug that is not tied to one specific mutation could, in theory, apply to a wider range of pancreatic tumors than a single-mutation inhibitor.

Wainberg framed the data as relevant to planning "the next wave of RAS-targeted therapies" with the ultimate goal of replacing chemotherapy. That is a stated aspiration of the investigator, not a result of this trial.

What to know for the USMLE: RAS, KRAS, and pancreatic adenocarcinoma

This news ties together several recurring exam themes. The points below are standard textbook knowledge, not findings from the trial.

• RAS/KRAS is a proto-oncogene encoding a small GTPase on the inner surface of the cell membrane. It cycles between inactive (GDP-bound) and active (GTP-bound) states.
• Activation and inactivation: growth factor receptor signaling recruits GEFs (such as SOS), which promote GDP-to-GTP exchange. GAPs speed up intrinsic GTPase activity and turn RAS off. Oncogenic mutations, classically at codon 12, impair GTP hydrolysis, so RAS stays "on."
• Downstream pathways: active RAS signals through RAF–MEK–ERK (MAPK) and PI3K–AKT, driving proliferation and survival. This is a gain-of-function, dominant mechanism: one mutated allele is enough.
• Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic cancer. KRAS is the classic early driver, followed by CDKN2A, TP53, and SMAD4 inactivation as precursor lesions (PanIN) progress to invasive cancer.
• Risk factors: smoking is the strongest modifiable risk factor. Others include chronic pancreatitis, diabetes, obesity, and certain hereditary syndromes.
• Clinical clues: a head-of-pancreas tumor causes painless jaundice and a palpable nontender gallbladder (Courvoisier sign). Other associations are Trousseau syndrome (migratory thrombophlebitis) and weight loss. CA 19-9 is a tumor marker for monitoring, not a screening test.
• Treatment concepts: resection (Whipple procedure) is for localized, resectable disease. Metastatic disease is treated systemically, and the classic option has been cytotoxic chemotherapy. Targeted therapy blocks a specific oncogenic driver instead.
• KRAS across cancers: KRAS-mutant colorectal cancer does not respond to EGFR antibodies (cetuximab, panitumumab), because the pathway is activated downstream of the receptor. Inhibitors targeting the KRAS G12C variant exist for some other tumors, and G12C is a single, specific mutation. This is the contrast with the broader RAS-blocking approach described here.
• Trial vocabulary: know median overall survival, randomization, and subgroup analysis. A consistent direction of effect across subgroups is reassuring, but subgroup analyses are generally hypothesis-generating.

Limitations

Several caveats apply, and the source states some of them directly.

• This is a secondary analysis. The 13.2 versus 6.7 month figures come from the earlier primary results. The new work examined whether the benefit was consistent across subgroups. Subgroup findings carry less statistical certainty than the primary endpoint.
• Some subgroups were small. The source says so, and it is the main reason for caution about individual mutation groups, including the group with no identified RAS mutation.
• Follow-up is still limited. Researchers note that further follow-up is needed to understand long-term benefits across different patient populations.
• Mutation-specific response may differ. Wainberg himself said the response may vary depending on the individual mutation. "Consistent benefit" therefore does not mean identical benefit in every group.
• The source material is silent on some topics. It does not report side effects, quality of life, or detailed numbers by subgroup. This article cannot comment on them.
• Context: the setting is previously treated metastatic disease. The results should not be extrapolated to localized disease or other cancers. Nothing here is a recommendation for any individual patient.

FAQ

What is daraxonrasib?

Daraxonrasib is an oral targeted therapy designed to block multiple forms of the active RAS protein, both mutated and nonmutated. According to the source, it is marketed as RASONQUE and received FDA approval in August 2026 for certain adults with metastatic pancreatic adenocarcinoma.

What did the RASolute 302 trial show?

In about 500 previously treated patients with metastatic pancreatic cancer, median survival was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy. The new analysis found that survival outcomes consistently favored the drug across RAS mutation groups, chemotherapy comparators, and prior-treatment settings.

Why is RAS so important in pancreatic cancer?

More than 90% of pancreatic cancers have mutations in RAS genes. Mutated RAS can send growth signals continuously, which drives tumor growth. For the USMLE, remember that KRAS is a GTPase that stays GTP-bound and active when mutated.

Key takeaways

• In the phase 3 RASolute 302 trial, daraxonrasib was associated with median survival of 13.2 months versus 6.7 months with chemotherapy in previously treated metastatic pancreatic cancer. A new analysis found consistent benefit across RAS mutation groups and chemotherapy comparators.
• For Step 1 and Step 2 CK, link this to KRAS biology: a GTPase locked in its GTP-bound state, signaling through RAF–MEK–ERK and PI3K–AKT, in the setting of pancreatic ductal adenocarcinoma.
• Treat the subgroup data with caution. Some subgroups were small, follow-up is ongoing, and the response may differ by individual mutation.